

ASTRAZENECA PLC  
Form 6-K  
February 01, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For the month of February 2019

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge CB2 0AA  
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):  
82- \_\_\_\_\_

AstraZeneca PLC

INDEX TO EXHIBITS

1.  
Total Voting Rights

1 February 2019 15:00 GMT

Transparency Directive  
Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 January 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,267,101,448 ordinary shares of US\$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,267,101,448.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit [astrazeneca.com](http://astrazeneca.com) and follow us on Twitter@AstraZeneca.

Media Relations

|                         |           |                  |
|-------------------------|-----------|------------------|
| Gonzalo Viña            | UK/Global | +44 203 7495916  |
| Karen Birmingham        | UK/Global | +44 203 7495634  |
| Rob Skelding            | UK/Global | +44 203 7495821  |
| Matt Kent               | UK/Global | +44 203 7495906  |
| Jennifer Hursit         | UK/Global | +44 203 7495762  |
| Christina M Hägerstrand | Sweden    | +46 8 552 53 106 |
| Michele Meixell         | US        | +1 302 885 2677  |

Investor Relations

|                     |  |                 |
|---------------------|--|-----------------|
| Thomas Kudsk Larsen |  | +44 203 7495712 |
| Henry Wheeler       | Oncology                               | +44 203 7495797 |
| Christer Gruvris    | BioPharma - Cardiovascular; Metabolism | +44 203 7495711 |
| Nick Stone          | BioPharma - Respiratory; Renal         | +44 203 7495716 |
| Josie Afolabi       | Other                                  | +44 203 7495631 |

Edgar Filing: ASTRAZENECA PLC - Form 6-K

|                    |                                    |                  |
|--------------------|------------------------------------|------------------|
| Craig Marks        | Finance; Fixed Income              | +44 7881 615764  |
| Jennifer Kretzmann | Retail Investors; Corporate Access | +44 203 7495824  |
| US toll-free       |                                    | +1 866 381 72 77 |

Adrian Kemp  
Company Secretary  
AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 February 2019

By: /s/ Adrian Kemp  
Name: Adrian Kemp  
Title: Company Secretary